HK Stock Movement | FUSEN PHARM (01652) Surges Over 7% as Its "Azilsartan Potassium Tablets" Gain Market Approval

Stock News

Nov 17, 2025

FUSEN PHARM (01652) rose more than 7%, reaching HK$0.88 by the time of writing, with a trading volume of HK$1.264 million. The surge follows the company's announcement on November 14 that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, received approval from China's National Medical Products Administration for the market launch of "Azilsartan Potassium Tablets" (brand name: Kuainuoping), indicated for the treatment of primary hypertension.

The main component of "Azilsartan Potassium Tablets," azilsartan potassium, is an angiotensin II receptor antagonist. After oral absorption, it rapidly converts into the active metabolite azilsartan, which lowers blood pressure by blocking the angiotensin II hormone.

Notably, within the overall renin-angiotensin system (RAS) market, over 80% of the share is occupied by "sartan"-class drugs, including monotherapies and combination therapies. In 2022, sales of these drugs exceeded RMB 10 billion, highlighting their significant role in the hypertension treatment landscape.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1131439795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131439795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131439795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131439795","market":"nz","top_or_hot":-1,"title":"HK Stock Movement | FUSEN PHARM (01652) Surges Over 7% as Its \"Azilsartan Potassium Tablets\" Gain Market Approval","media":"Stock News","content":"<p>FUSEN PHARM (01652) rose more than 7%, reaching HK$0.88 by the time of writing, with a trading volume of HK$1.264 million. The surge follows the company's announcement on November 14 that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, received approval from China's National Medical Products Administration for the market launch of \"Azilsartan Potassium Tablets\" (brand name: Kuainuoping), indicated for the treatment of primary hypertension.</p>\n<p>The main component of \"Azilsartan Potassium Tablets,\" azilsartan potassium, is an angiotensin II receptor antagonist. After oral absorption, it rapidly converts into the active metabolite azilsartan, which lowers blood pressure by blocking the angiotensin II hormone.</p>\n<p>Notably, within the overall renin-angiotensin system (RAS) market, over 80% of the share is occupied by \"sartan\"-class drugs, including monotherapies and combination therapies. In 2022, sales of these drugs exceeded RMB 10 billion, highlighting their significant role in the hypertension treatment landscape.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | FUSEN PHARM (01652) Surges Over 7% as Its \"Azilsartan Potassium Tablets\" Gain Market Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | FUSEN PHARM (01652) Surges Over 7% as Its \"Azilsartan Potassium Tablets\" Gain Market Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-17 13:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FUSEN PHARM (01652) rose more than 7%, reaching HK$0.88 by the time of writing, with a trading volume of HK$1.264 million. The surge follows the company's announcement on November 14 that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, received approval from China's National Medical Products Administration for the market launch of \"Azilsartan Potassium Tablets\" (brand name: Kuainuoping), indicated for the treatment of primary hypertension.</p>\n<p>The main component of \"Azilsartan Potassium Tablets,\" azilsartan potassium, is an angiotensin II receptor antagonist. After oral absorption, it rapidly converts into the active metabolite azilsartan, which lowers blood pressure by blocking the angiotensin II hormone.</p>\n<p>Notably, within the overall renin-angiotensin system (RAS) market, over 80% of the share is occupied by \"sartan\"-class drugs, including monotherapies and combination therapies. In 2022, sales of these drugs exceeded RMB 10 billion, highlighting their significant role in the hypertension treatment landscape.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1131439795","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131439795","pubTimestamp":1763357894,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FUSEN PHARM (01652) rose more than 7%, reaching HK$0.88 by the time of writing, with a trading volume of HK$1.264 million. The surge follows the company's announcement on November 14 that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","01652":"福森药业"},"translate_title":"港股动向|福森药业(01652)“阿齐沙坦钾片”获市场批准涨超7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01652":1},"content_text":"FUSEN PHARM (01652) rose more than 7%, reaching HK$0.88 by the time of writing, with a trading volume of HK$1.264 million. The surge follows the company's announcement on November 14 that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, received approval from China's National Medical Products Administration for the market launch of \"Azilsartan Potassium Tablets\" (brand name: Kuainuoping), indicated for the treatment of primary hypertension.\nThe main component of \"Azilsartan Potassium Tablets,\" azilsartan potassium, is an angiotensin II receptor antagonist. After oral absorption, it rapidly converts into the active metabolite azilsartan, which lowers blood pressure by blocking the angiotensin II hormone.\nNotably, within the overall renin-angiotensin system (RAS) market, over 80% of the share is occupied by \"sartan\"-class drugs, including monotherapies and combination therapies. In 2022, sales of these drugs exceeded RMB 10 billion, highlighting their significant role in the hypertension treatment landscape.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}